The city of Miami, Florida, currently has 18 active clinical trials seeking participants for Dementia research studies.
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Recruiting
This trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Gender:
All
Ages:
Between 65 years and 90 years
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Miami, Florida +6 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/22/2024
Locations: Premier Clinical Research Institute Inc., Miami, Florida +1 locations
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Recruiting
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
04/17/2024
Locations: Miami, Florida, Miami, Florida +1 locations
Conditions: Apathy in Dementia
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/05/2024
Locations: Homestead Associates in Research Site# 797, Miami, Florida +35 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
03/26/2024
Locations: Clinical Research Site #840-118, Miami, Florida +4 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
03/26/2024
Locations: Clinical Research Site, Miami, Florida +4 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Phenotype, Genotype and Biomarkers 2
Recruiting
The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genoty... Read More
Gender:
All
Ages:
7 years and above
Trial Updated:
03/18/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Clinical Procedures to Support Research in ALS
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Combating Alzheimer's Through Sleep and Exercise
Recruiting
The purpose of this research is to see how sleep and exercise affects dementia risk over time.
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
02/29/2024
Locations: University of Miami Hospitals, Miami, Florida
Conditions: Alzheimer Disease, Dementia
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
01/17/2024
Locations: Miami VA Medical Center, Miami, Florida +1 locations
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
01/16/2024
Locations: Central Miami Medical Institute, Miami, Florida +5 locations
Conditions: Agitation, Alzheimer's Type Dementia
Genetic Studies in Familial Dementia
Recruiting
The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups. This includes a number of neurological diseases such as early and late-onset Alzheimer disease, mild cognitive impairment, and other dementias.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: University of Miami, Miami, Florida
Conditions: Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia